CBR1 and Dravet syndrome: Pharmacological inhibitors of CBR1 are being explored for use as adjunctive therapy in chemotherapeutic regimes which include doxorubicin because CBR1 metabolises doxorubicin to cardiotoxic daunorubicin which limits its use, particularly in DS patients [21,37,65].